Prof Sagar Lonial (Emory University, Atlanta, USA) and Dr Paul Richardson (Dana-Farber Cancer Institute, Boston, USA) discuss the highlights in multiple myeloma treatment arising from day one of ASCO 2016.
They discuss the results and implications of data coming from upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy.
This is a randomised phase III study of the European myeloma network with results showing that PFS is significantly prolonged in pts randomised to HDM (OS not yet mature).
One of the key highlights from day one looked at a meta-analysis of three studies (IFM 2005-02, CALGB 100104 [Alliance], GIMEMA RV-209) that had previously demonstrated PFS in patients with multiple myeloma, but were not originally powered for OS.
This meta-analysis now demonstrates that lenalidomide maintenance after high-dose melphalan and ASCT significantly prolonged OS versus placebo/no maintenance.
Some early phase trials were also discussed including a phase I/II trial of ixazomib, an oral proteasome inhibitor, cyclophosphamide, and dexamethasone for newly diagnosed multiple myeloma (NDMM).
A phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma and a phase I/II study of carfilzomib, pomalidomide, and dexamethasone (KPd) in patients with relapsed/refractory multiple myeloma (RRMM).
This programme has been supported by an unrestricted educational grant from Celgene